Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates
Advancements in Clinical Trials and AI Platform Highlighted Amid Financial Discipline
Source: yahoo.com
📰 Lantern Pharma News
Page 3 - Lantern Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lantern Pharma. Real-time updates on events, politics, business and more.
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
DALLAS--(BUSINESS WIRE)--Nov 8, 2023--
South Korea British Columbia United States Kishor Bhatia John Laterra Johns Hopkins Medicine Kennedy Krieger Institute
Source: eagletribune.com
Building a Path to Cure for Patients With NSCLC Who Have Never Smoked
How patients acquire NSCLC plays a role in health outcomes, with never-smoker patients having genetically different disease than the same disease in smokers.
United States Centers For Disease Translational Lung Cancer Research Lantern Pharma Disease Control Lung Cancer
Source: pharmacytimes.com
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET -November 01, 2023 at 08:10 am EDT
Webcast to be held Wednesday, November 8th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. ...
Lantern Pharma Inc Securities Exchange Exchange Commission On Lantern Pharma Panna Sharma Chief Executive Officer
Source: marketscreener.com
High-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, Immunomic, Inovio
/PRNewswire/ -- DelveInsights High-grade Glioma Market Insights report includes a comprehensive understanding of current treatment practices, high-grade...
Source: prnewswire.com
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET -October 10, 2023 at 08:10 am EDT
Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR®, with multiple...
New York United States Lantern Pharma Inc Securities Exchange Starlight Therapeutics Inc Exchange Commission On
Source: marketscreener.com
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR®, as a potential therapy for a wide range of advanced...
United States San Antonio Exchange Commission On American Association For Cancer Research Lantern Pharma Inc Securities Exchange
Source: marketscreener.com
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's Lymphomas
This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR®. LP-284 is the second of Lantern’s...
United States Exchange Commission On Lantern Pharma Inc Starlight Therapeutics Inc Drug Administration Securities Exchange
Source: marketscreener.com
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's Lymphomas Seite 1
18.09.2023 - Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR, with multiple clinical stage drug programs, today ... Seite 1
Source: wallstreet-online.de